Dr. Wes Fisher joins the show to continue highlighting ABIM recertification and the MOC program following a petition that has gathered over 12,000 signatures to end this program. Dr. Fisher is a clinical cardiac electrophysiologist at NorthShore University HealthSystem in Evanston, IL; he is also a clinical Associate Professor at the University of Chicago Pritzker School of Medicine. Dr. Fisher is triple board-certified in Internal Medicine (Grandfathered per the ABIM), cardiology, and cardiac electrophysiology. He is due for his FOURTH re-certification in cardiology after 12/31/2023 and FOURTH re-certification in EP after 12/31/2023.
The process of re-certification and MOC became a core center in Dr. Fisher’s advocacy on behalf of the physicians. He co-founded Practicing Physicians of America to advocate and educate and has done significant investigative work on the ABIM; you can see much of his writing on his blog as well as many other outlets.
Why does a respected EP physician, with over 3 decades of experience and thousands of patients seen, need to do this re-certification again and pay yearly dues? Please listen to this exclusive revealing podcast and share with your colleagues.
This is another ABIM-related MUST LISTEN podcast.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
